Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratympanic Dexamethasone with Hyaluronic Acid for SSNHL
NCT06878599Phase 4Not yet recruiting
- Sponsor
- Assiut University
- Start
- May 2025
- Primary completion
- Oct 2027
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of hyaluronic acid in sudden sensorineural hearing loss (SSHL) (2 arms), sponsored by Assiut University. Primary endpoints: Degree of hearing improvement and Assessing each frequency difference. Planned start May 2025; status: not yet recruiting.
02
Drugs
hyaluronic acid
03
Conditions
sudden sensorineural hearing loss (SSHL)
Beyond the preview
Go deeper on NCT06878599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06878599.